Methods for treating IFN-γ mediated diseases using human anti-IFN-γ neutralizing antibodies as selective IFN-gamma pathway inhibitors
View Patent ↗This invention provides antibodies that interact with or bind to human interferon-gamma (IFN-γ) and methods for treating IFN-γ mediated diseases by administering a pharmaceutically effective amount of antibodies to IFN-γ. Methods of detecting the amount of IFN-γ in a sample using antibodies to IFN-γ are also provided.
1. A method for treating a patient having systemic lupus erythematosus comprising administering to the patient a human anti-human IFNγ antibody, wherein the antibody comprises a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO:34, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO:35, a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO:36, a light chain CDR1 comprising the amino acid sequence of SEQ ID NO:38, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO:41, and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO:43.
2. The method of claim 1 , wherein the antibody comprises the amino acid sequence of SEQ ID NO:6.
3. The method of claim 1 , wherein the patient has lupus nephritis.
4. The method of claim 3 , wherein the antibody comprises the amino acid sequence of SEQ ID NO:6.
5. The method of claim 2 , wherein the antibody comprises the amino acid sequence of SEQ ID NO:8.
6. The method of claim 4 , wherein the antibody comprises the amino acid sequence of SEQ ID NO:8.
7. The method of claim 1 , wherein the antibody comprises the amino acid sequence of SEQ ID NO:8.
8. The method of claim 3 , wherein the antibody comprises SEQ ID NO:8.
9. A method for treating a patient having an inflammatory bowel disease comprising administering to the patient a human anti-human IFNγ antibody, wherein the antibody comprises a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO:34, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO:35, a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO:36, a light chain CDR1 comprising the amino acid sequence of SEQ ID NO:38, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO:41, and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO:43.
10. The method of claim 9 , wherein the antibody comprises the amino acid sequence of SEQ ID NO:6.
11. The method of claim 9 , wherein the patient has Crohn's disease.
12. The method of claim 11 , wherein the antibody comprises the amino acid sequence of SEQ ID NO:6.
13. The method of claim 10 , wherein the antibody comprises the amino acid sequence of SEQ ID NO:8.
14. The method of claim 11 , wherein the antibody comprises the amino acid sequence of SEQ ID NO:8.
15. The method of claim 9 , wherein the antibody comprises the amino acid sequence of SEQ ID NO:8.
16. The method of claim 12 , wherein the antibody comprises SEQ ID NO:8.
17. A method for treating a patient having psoriasis comprising administering to the patient a human anti-human IFNγ antibody, wherein the antibody comprises a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO:34, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO:35, a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO:36, a light chain CDR1 comprising the amino acid sequence of SEQ ID NO:38, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO:41, and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO:43.
18. The method of claim 17 , wherein the antibody comprises the amino acid sequence of SEQ ID NO:6.
19. The method of claim 17 , wherein the antibody comprises the amino acid sequence of SEQ ID NO:8.
20. The method of claim 18 , wherein the antibody comprises the amino acid sequence of SEQ ID NO:8.